ReviewClinical and experimental immunology2021
Clinical and neuroimaging findings in MOGAD-MRI and OCT.
Review in Clinical and experimental immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brain atrophy in NMOSD and MOGAD: a meta-analysis of volumetric and DTI biomarkers.Frontiers in neurology · 2025Pooled it
- U-Fiber Enhancement in MOGAD: Extending the Meningo-Cortical Spectrum.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- When is the Radiologically Isolated Syndrome already Multiple Sclerosis According to the 2024 McDonald Criteria?Current neurology and neuroscience reports · 2026Review
- MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Clinical, imaging, and immunotherapeutic features in MOGAD: a retrospective real-world cohort in Northern China.Therapeutic advances in neurological disorders · 2026Article
- Pathology of the conus medullaris and cauda equina. Beyond the usual suspects.Insights into imaging · 2025Article
- [Optic neuritis-Patient sees nothing, doctor sees nothing? : A case of myelin oligodendrocyte glycoprotein antibody-associated optic neuritis].Die Ophthalmologie · 2025Article
- Current imaging applications, radiomics, and machine learning modalities of CNS demyelinating disorders and its mimickers.Journal of neurology · 2025Review
- Management and burden of disease in people with myelin oligodendrocyte glycoprotein antibody-associated disease: data from an international, cross-sectional survey.Journal of neurology · 2025Article
- Acute urinary retention as first sign of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) - Case report and literature review.Urology case reports · 2025Article
- An atypical cause of optic neuritis: Myelin oligodendrocyte glycoprotein antibody disease (MOGAD).Radiology case reports · 2025Article
- Barriers in Healthcare to the Use of Optical Coherence Tomography Angiography in Multiple Sclerosis.Neurology and therapy · 2025Review
- Biomarkers for diagnosis and prognosis of myelin oligodendrocyte glycoprotein antibody-associated disease - review article.Frontiers in immunology · 2025Review
- Interleukin-6 targeting antibodies for the treatment of Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): A review of current literature.AIMS neuroscience · 2025Review
- Translational insights from EAE models : decoding MOGAD pathogenesis and therapeutic innovation.Frontiers in immunology · 2025Review
- Pediatric Neuroimaging of Multiple Sclerosis and Neuroinflammatory Diseases.Tomography (Ann Arbor, Mich.) · 2024Review
- The real-world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody-associated disease criteria in a Latin American cohort.European journal of neurology · 2024Article
- Impact of autoantibodies against myelin oligodendrocyte glycoprotein in paediatric acquired demyelinating disease: Intellectual functioning and academic performance.European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · 2024Article
- Rapid differentiation of MOGAD and MS after a single optic neuritis.Journal of neurology · 2024Article
- NMOSD and MOGAD: an evolving disease spectrum.Nature reviews. Neurology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are rare in both children and adults, and have been recently suggested to be an autoimmune neuroinflammatory group of disorders that are different from aquaporin-4 autoantibody-associated neuromyelitis optica spectrum disorder and from classic multiple sclerosis. In-vivo imaging of the MOGAD patient central nervous system has shown some distinguishing features when evaluating magnetic resonance imaging of the brain, spinal cord and optic nerves, as well as retinal imaging using optical coherence tomography. In this review, we discuss key clinical and neuroimaging characteristics of paediatric and adult MOGAD. We describe how these imaging techniques may be used to study this group of disorders and discuss how image analysis methods have led to recent insights for consideration in future studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.